The FDA advisory panel's 10-1 vote against MDMA (ecstasy) for PTSD treatment underscores the importance of The Drake Center's safe and effective approach. The panel cited flawed data, questionable research, and significant drug risks, including heart problems and potential abuse.
With 13 million adults in the U.S. suffering from PTSD annually, the setback for MDMA therapy highlights the crucial role of ketamine. As Dr. Cassius Drake states, "Ketamine is an FDA-approved medication with proven safety and therapeutic profiles, which we will continue to use effectively."
#TheDrakeCenter #KetamineTherapy #PTSDTreatment #FDA #MDMA
Негізгі бет Ruling against FDA approval of MDMA offers proof of the effective Drake Center approach
Пікірлер